Please assess the completion status of the following clinical trial:

Trial Title: Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically\* confirmed follicular non-Hodgkin lymphoma (NHL)~  * Previously untreated disease~ * WHO classification grade 1, 2, or 3a (\> 15 centroblasts per high power field with centrocytes present) that is stage III, IV, or bulky (i.e., single mass ≥ 7 cm in any unidimensional measurement) stage II disease NOTE: \*Bone marrow biopsies as the sole means of diagnosis are not acceptable, but they may be submitted in conjunction with nodal biopsies; fine-needle aspirates are not acceptable for diagnosis~* Confirmed CD20 antigen expression by flow cytometry or immunohistochemistry~* Measurable disease by physical examination or imaging studies~  * Any tumor mass \> 1 cm is acceptable~ * No nonmeasurable disease only, including any of the following:~    * Bone lesions~   * Ascites~   * Pleural/pericardial effusion~   * Lymphangitis cutis/pulmonis~   * Bone marrow (involvement by NHL should be noted)~* No known CNS involvement by lymphoma~* Required to participate in companion FDG-PET imaging study CALGB 580701~PATIENT CHARACTERISTICS:~* ECOG performance status ≤ 2~* Absolute neutrophil count ≥ 1,000/μL~* Platelet count ≥ 50,000/μL~* Patients with HIV infection are eligible provided they meet the following criteria:~  * No evidence of coinfection with hepatitis B or C~ * CD4+ cell count ≥ 400/mm\^3~ * No evidence of resistant strains of HIV~ * If not on anti-HIV therapy, HIV viral load \< 10,000 copies HIV RNA/mL~ * If on anti-HIV therapy, HIV viral load \< 50 copies HIV RNA/mL~ * No history of AIDS-defining conditions~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 3 months after completion of study therapy~* No known Human Anti-Chimeric Antibody (HACA)-positivity~PRIOR CONCURRENT THERAPY:~* No prior therapy for NHL including chemotherapy, radiotherapy, or immunotherapy (e.g., monoclonal antibody-based therapy)~* More than 2 weeks since prior corticosteroids except for maintenance therapy for non-malignant disease~* No concurrent dexamethasone or other steroids as antiemetics except for the following circumstances:~  * Treatment of acute infusion reactions according to institutional procedures~* No concurrent hormonal therapy except steroids for adrenal failure OR hormones for non-disease-related conditions (e.g., insulin for diabetes)~* No other concurrent chemotherapeutic agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Epratuzumab Plus Rituximab (Type: EXPERIMENTAL): Induction Therapy (Month 1): Epratuzumab 360 mg/m\^2 by IV days 1, 8, 15 \& 22; Rituximab 375 mg/m\^2 by IV day 3, 8, 15 \& 22~Extended Induction (Weeks 12, 20, 28 \& 36) Epratuzumab 360 mg/m\^2 by IV weeks 12, 20, 28 \& 36; Rituximab 375 mg/m\^2 by IV weeks 12, 20, 28 \& 36

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete